|
Ivor Royston, M.D., is an oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines.〔Fikes, Bradley J. ''Only time eludes forever quizzical science maverick: Ivor Royston, president of San Diego Regional Cancer Center,'' ''San Diego Business Journal,'' June 13, 1994.〕〔("Why San Diego Has Biotech" ), Fikes, Bradley J. ''San Diego Metropolitan,'' April 1999. Accessed June 20, 2008.〕〔("Biotech Eden" ), Wilson, Elizabeth K. ''Chemical & Engineering News,'' March 5, 2001. Accessed June 20, 2008.〕〔("CONNECT Inducts Dr. Ivor Royston into Entrepreneur Hall of Fame" ), ''Genetic Engineering & Biotechnology News,'' June 14, 2006. Accessed June 20, 2008.〕〔("A legend in biotech world" ), Crabtree, Penni. ''The San Diego Union-Tribune,'' Dec. 14, 2004. Accessed June 20, 2008.〕〔("Innovation Prospectors: San Diegans ply a river of ideas for biotech gold" ), Acello, Rich. ''San Diego Magazine,'' June 2008. Accessed June 20, 2008.〕 He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.〔("Profiles in Innovation Series: Von Liebig Forum" ), UCTV: UC San Diego, June 26, 2006. Accessed June 20, 2008.〕〔("8th Shanghai International Biotechnology and Pharmaceutical Forum" ) Bio-Forum 2006, Apr. 25-27, 2006. Accessed June 20, 2008.〕 One of Dr. Royston's most significant achievements may be his successful efforts to partner academic medical research with industry to take potential treatments more quickly from the benchtop to the bedside.〔〔〔〔 After co-founding the first biotechnology company in San Diego, California, he and his associates went on to form or invest in dozens of other biotechs, laying the foundation of the region's thriving biotech cluster, one of the three largest in the United States. As a venture capitalist, Dr. Royston invests in start-up companies that have promising technologies for treating and potentially curing diseases, including various forms of cancer.〔(【引用サイトリンク】publisher=Forward Ventures )〕〔("Ivor Royston, MD" ), ''VentureForth,'' 2005. Accessed June 20, 2008.〕〔("Ivor Royston profile" ), ''LinkedIn,'' 2008. Accessed June 20, 2008.〕 — Ivor Royston Born in Retford, England, Dr. Royston emigrated to the United States with his family in 1954 at age 9, and later, as a 14-year-old, he declared that he would devote his life to curing cancer. Unlike many future scientists, his passion also extended to commerce. This early interest in business manifested itself in a Washington, D.C., high-school investment club of 16 boys — dubbed the Chessmen — that he founded with friends. He also bought and operated an ice cream truck to earn money for college. These divergent interests — medicine and business — would one day catapult Dr. Royston beyond his peers, transforming San Diego's economy while improving the health and lives of tens of thousands of patients along the way.〔("Ivor Royston, MD" ), ''Conde Nast Portfolio.com:,'' 2008. Accessed June 20, 2008.〕 ==Accomplishments== In 1978 Royston, then an assistant professor at the University of California-San Diego, bridged a chasm between academia and the marketplace, triggering a paradigm shift that forever changed San Diego's medical research community and led to the region's establishment as a leading international biotech clusters.〔〔〔("Innovation Prospectors: San Diegans ply a river of ideas for biotech gold" ), Acello, Rich. ''San Diego Magazine,'' June 2008. Accessed June 20, 2008.〕 Royston's reasoning was that private enterprise clearly provided the fastest way to get new, life-saving medicines from the research bench top to the patient's bedside. While serving as a researcher and a practicing physician at UCSD, Royston felt the frustration at the long process required to deliver innovative treatments to patients. That frustration fueled his decisive action to work towards eliminating the disconnect between research and clinical application by founding Hybritech with fellow scientist Howard Birndorf in 1978.〔("Cancer Researcher Turned Venture Capitalist" ), ''San Diego Metropolitan,'' November 2002. Accessed June 20, 2008.〕 The idea behind Hybritech was to harness monoclonal antibodies to quickly diagnose and treat diseases. Financier Brook Byers, of Kleiner Perkins Caufield & Byers, realized the importance of the science and recognized the longer-term value of the budding entrepreneurs' passion, energy and commitment. His firm provided the $300,000 start-up funding, and Hybritech's first product, antibodies for the hepatitis B virus, reached the research market in 1980. The PSA test developed later by the company for the early diagnosis of prostate cancer has benefited countless victims of this deadly disease and set the stage for new blood tests for the early detection of cancer. Hybritech went public in 1981 and, five years later, pharmaceutical giant Eli Lilly and Company paid $480 million for the company.〔("The Birth of Biotech: How one company helped seed San Diego's industry" ), Chi, Kelly Rae. ''The Scientist.'' Accessed June 20, 2008.〕〔("Forbes Profile: Ivor Royston, MD" ), ''Forbes.com,'' 2008. Accessed June 20, 2008.〕 — Chemical Heritage Newsmagazine Dr. Royston went on to co-found IDEC Pharmaceuticals (now Biogen Idec) and the San Diego Regional Cancer Center (now the Sidney Kimmel Cancer Center). More than 50 San Diego companies trace their lineage directly to Hybritech, its founders and early employees. Among those are IDEC, San Diego's biggest biotech success story, with a billion dollars in sales for its lymphoma treatment Rituxan. Others include Amylin, Cancervax, Gen-Probe, Ligand Pharmaceuticals and Nanogen.〔(【引用サイトリンク】publisher=Forward Ventures )〕 In addition to Hybritech, Dr. Royston has been directly involved in the founding or funding of many biotech companies as an entrepreneur and venture capitalist. These companies include: Applied Molecular Evolution, Avalon Pharmaceuticals, Combichem (acquired by Dupont), Corixa, Dynavax Technologies Corporation, Genesys Therapeutics (merged with Somatix and acquired by Cell Genesys), Genquest (acquired by Corixa), HenaQuest, IDEC Pharmaceuticals (merged with Biogen to form Biogen Idec), LigoCyte, Micromet (formerly CancerVax), Morphotek (Acquired by Eisai Corporation), Sequana Therapeutics (merged with Arris to form AXYS and acquired by Celera Genomics), Syndax, Targegen, Triangle Pharmaceuticals (acquired by Gilead) and Variagenics (merged with Hyseq Pharmaceuticals to form Nuvelo).〔(【引用サイトリンク】publisher=Forward Ventures )〕〔( "Ivor Royston, Adventures in Biotechnology" ), Dionisio, Jennifer. ''Chemical Heritage Newsmagazine,'' Spring 2007, Vol. 25, No. 1. Accessed June 20, 2008.〕 The contributions to medicine that all of the companies Dr. Royston has been involved with are incalculable. — Dr. Daniel Gold 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ivor Royston」の詳細全文を読む スポンサード リンク
|